# Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy

> **NCT04173442** · — · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 581 (actual)

## Conditions studied

- Atopic Dermatitis (AD)
- Asthma

## Interventions

- **DRUG:** dupilumab

## Key facts

- **NCT ID:** NCT04173442
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-24
- **Primary completion:** 2025-11-04
- **Final completion:** 2025-11-04
- **Target enrollment:** 581 (ACTUAL)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04173442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04173442, "Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04173442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*